Home » Stocks » VVUS

Vivus, Inc. (VVUS)

Jul 17, 2020 - VVUS was delisted due to bankruptcy and now trades as VVUSQ
Stock Price: $0.467 USD -0.054 (-10.29%)
Updated Jul 16, 2020 4:00 PM EDT
Market Cap 8.34M
Revenue (ttm) 73.25M
Net Income (ttm) -28.77M
Shares Out 17.87M
EPS (ttm) -2.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Jul 16, 2020
Last Price $0.467
Previous Close $0.520
Change ($) -0.054
Change (%) -10.29%
Day's Open -
Day's Range 0.460 - 0.500
Day's Volume 0
52-Week Range 0.437 - 4.750

News

Hide News
GlobeNewsWire - 6 months ago

CAMPBELL, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-co...

GlobeNewsWire - 7 months ago

CAMPBELL, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has updated its agreement regarding its co...

Seeking Alpha - 8 months ago

VIVUS, Inc's (VVUS) CEO John Amos on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

CAMPBELL, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced an agreement regarding its corporate debt with IEH ...

Seeking Alpha - 9 months ago

VIVUS Finding Support After Launch Of Its Remote Health Platform

GlobeNewsWire - 9 months ago

CAMPBELL, Calif., April 03, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the completion of its previously announced regist...

Benzinga - 9 months ago

Vivus (NASDAQ: VVUS) shares were trading lower on Wednesday, after the company priced its 7.22 million share common stock offering at $1.60 per share.

GlobeNewsWire - 9 months ago

CAMPBELL, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has entered into definitive agreements wi...

Benzinga - 9 months ago

Shares of biopharma company VIVUS, Inc. (NASDAQ: VVUS) are skyrocketing following an announcement concerning launch plans for telemedicine services.

24/7 Wall Street - 9 months ago

Vivus Inc. (NASDAQ: VVUS) shares absolutely exploded on Tuesday after the company announced that it was accelerating the launch of the telemedicine and remote monitoring modules of the Vivus H...

GlobeNewsWire - 9 months ago

Virtual office visits and smart health devices available through the VIVUS Health Platform give physicians new tools for optimizing patient care and protecting the health of those at increased...

Seeking Alpha - 10 months ago

VIVUS, Inc. (VVUS) CEO John Amos on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 10 months ago

VIVUS, Inc. (VVUS) CEO VIVUS, Inc.

GlobeNewsWire - 10 months ago

- Company to host conference call today at 4:30pm ET -

GlobeNewsWire - 10 months ago

-Post-marketing study designed to evaluate Qsymia as an approach to weight management in a growing patient population with significant unmet medical need-

GlobeNewsWire - 11 months ago

- VIVUS to Receive Milestone Payment from Alvogen; Significant Worldwide Growth Potential for Qsymia -

24/7 Wall Street - 11 months ago

Vivus Inc. (NASDAQ: VVUS) shares jumped on Wednesday after the company announced a crucial approval by the U.S.

GlobeNewsWire - 11 months ago

CAMPBELL, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has ap...

GlobeNewsWire - 1 year ago

-Data published in Journal of General Internal Medicine show that patients using Qsymia and other weight loss tools, lost at least 5% of body weight loss compared with those not using Qsymia-

GlobeNewsWire - 1 year ago

CAMPBELL, Calif., Dec. 31, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that on December 30, 2019 its board of directors ...

GlobeNewsWire - 1 year ago

-Data published in Diabetes, Obesity and Metabolism demonstrate that Qsymia provides statistically significant weight loss compared with placebo over an 8 week period, provide basis for ongoin...

Market Watch - 1 year ago

Shares of Vivus Inc. rose 9% in morning trading after the drugmaker said its weight-loss drug Qsymia can reduce binging frequency for patients with binge-eating disorder or bulimia nervosa.

GlobeNewsWire - 1 year ago

-Data published in International Journal of Eating Disorders show patients in the Qsymia group had 75% decrease in binge day frequency compared with 19% for placebo-

Seeking Alpha - 1 year ago

VIVUS, Inc. (VVUS) CEO John Amos on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

CAMPBELL, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that Eric W. Roberts and Allan L. Shaw have resig...

GlobeNewsWire - 1 year ago

CAMPBELL, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that John Amos, Chief Executive Officer, will par...

GlobeNewsWire - 1 year ago

CAMPBELL, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that European regulatory agencies in Sweden, Denm...

GlobeNewsWire - 1 year ago

CAMPBELL, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS,...

GlobeNewsWire - 1 year ago

-Conference in Seoul provides opportunity to introduce an international audience to the clinical safety and benefits of Qsymia following its approval in the Republic of Korea-

GlobeNewsWire - 1 year ago

-Data published in Surgery for Obesity and Related Diseases also show that patients in the Qsymia group lost more than twice as much weight during preoperative treatment compared with control ...

Seeking Alpha - 1 year ago

VIVUS, Inc. (VVUS) CEO John Amos on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

VIVUS, Inc. (VVUS) CEO John Amos on Q1 2019 Results - Earnings Call Transcript

About VVUS

VIVUS operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to tre... [Read more...]

Industry
Biotechnology
IPO Date
Apr 6, 1994
CEO
John P. Amos
Employees
59
Stock Exchange
NASDAQ
Ticker Symbol
VVUS
Full Company Profile

Financial Performance

In 2019, Vivus, Inc's revenue was $69.76 million, an increase of 7.22% compared to the previous year's $65.06 million. Losses were -$31.50 million, -14.74% less than in 2018.

Financial Statements